Article Text

Download PDFPDF

Thrombolytic therapy for submassive pulmonary embolus? PRO viewpoint
  1. Luke S Howard
  1. Correspondence to Dr Luke S Howard, National Pulmonary Hypertension Service, Hammersmith Hospital, Imperial College Healthcare NHS Trust, Du Cane Road, London W12 0HS, UK; l.howard{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

If we had robust evidence one way or the other to inform us on the use of thrombolytics in submassive pulmonary embolus (PE), we would not need this debate. But, we do not and, so, we do. The stakes are considered high both in favour and against thromobolysing submassive PE, so we cannot brush the debate under the carpet while we await the evidence. It is accepted that high-risk/massive PE, defined as haemodynamic instability, merits aggressive treatment due to unacceptable mortality, which outweighs the risk of haemorrhage. At the other end of the spectrum, patients with low-risk PE do not, such that they may even be treated as outpatients.

This leaves a grey area in between. When faced with a patient with a large thrombus load with a right ventricle (RV) that is dilated and pressure-loaded, but who is normotensive, as the attending clinician, we know they are at increased risk of death and long-term complications, such as chronic thromboembolic pulmonary hypertension (CTEPH).1 ,2 We may fall back on the Hippocratic Oath to ‘first, do no harm’, but the fuller translation reads ‘I will use treatments for the benefit of the ill in accordance with my ability and my judgment, but from what is to their harm and injustice I will keep them’. Thus, rather than hide behind a lack of evidence, we must review what we have and come to a balanced decision, and justify it.

In proposing the argument that submassive PE should be treated with thrombolysis, we must first accept that direct mortality due to the PE itself, not confounding conditions, remains unacceptably high with anticoagulation alone. A more aggressive strategy is required. As long as the benefits of thrombolysis outweigh the risks, then thrombolysis offers the best currently available approach. When this is coupled with the further benefits of likely reduction in CTEPH, the case becomes even stronger.

The American Heart Association (AHA)3 has proposed a definition of submassive PE as either:

  • RV dysfunction, defined as RV dilation on echocardiography or CT, systolic dysfunction on echocardiography, elevation of brain natiuretic peptide (BNP)/N-terminal pro BNP (NT-proBNP) or evidence of new RV strain on ECG; or

  • myocardial necrosis, defined as elevation of troponin I or T.

These measures either alone or in combination have been shown in many studies to be associated with worse survival, but this definition itself has not been prospectively studied. Jimenez et al4 collected data from 591 normotensive PE patients (those who had received thrombolysis at the physician's discretion were not included) and showed that there was a 10% overall mortality. Pulmonary embolism may often occur on the background of other serious medical conditions, which may themselves lead to death. In these cases, it is hard to see how thrombolysis could improve the outcome, but Jimenez et al demonstrated that the rate of PE death, as opposed to all cause death, was 6.7%. When some of the criteria for submassive PE were applied, the rate of PE-related mortality increased to 11% with a positive troponin, 12% with echocardiographic evidence of RV dysfunction and 10% with complete compression ultrasound evidence of deep vein thrombosis (DVT).

Presented with data such as these, we may ask why studies of thrombolysis have not shown improvement in mortality. The reasons may be twofold. The first is that patients recruited into studies may have less severe disease, either due to a looser definition of submassive PE or due to those with more severe signs of right heart dysfunction not being recruited at the physician's discretion in order they be thrombolysed outside the protocol. Looking at the largest trial to date of thrombolysis in submassive PE,5 only 31% of patients in the standard treatment arm had RV dysfunction on echocardiography and the mortality rate in that same arm was just over 2%. Contrast this with >10% mortality in the study by Jimenez et al4 if patients had one or more of RV dysfunction, positive troponin or DVT. The AHA document3 pools all the randomised thrombolysis studies in PE up to 2011, and only one has more than 100 patients in each arm5 and it is therefore also not surprising to appreciate that these studies will be underpowered to detect a significant reduction in mortality. The studies were performed in different categories of patients and over 40 years, making pooling difficult, although it is worth noting there was a 30% non-significant reduction in mortality in the patients receiving thrombolysis. We can perhaps therefore conclude that trials may be under-representative of the true mortality of submassive PE. Of interest, however, a study not included, due to later publication,6 randomised only patients with documented RV dysfunction on echocardiography, thus enriching the population, and in this study there was a significant reduction in PE-related mortality with 6/35 patients dying in the heparin group and 0/37 dying in the thrombolysis group.

The second reason that trials so far may not have shown a reduction in mortality is that they allow for thrombolysis in the event of haemodynamic collapse. To capture this effect, studies often combine mortality with haemodynamic collapse to detect a treatment response.5 ,7

The authors of the AHA document suggest that since the mortality seen in trials for submassive PE is less than 3%, even with highly effective therapy reducing mortality by 30%, trials will be unsuccessful in proving a mortality benefit, and thus surrogate endpoints should be used.3 Since we know that PE-related mortality is linked to RV dysfunction which in turn is largely caused by clot burden2 (likely to be a combination of burden in the lung and leg veins, since DVT increases the risk of death4), two good possible surrogates for mortality are haemodynamics and clot resolution.

A recent randomised study of thrombolysis in ‘moderate’ pulmonary embolism measured systolic pulmonary artery pressure (sPAP) as estimated on echocardiography as its primary endpoint. Thrombolysis versus anticoagulation resulted in a significantly lower sPAP at 48 h. Showing this fall in sPAP at such an early time point is critical to its credibility as a surrogate for PE-related mortality. This has also been documented in several other studies.3 If only patients with RV dysfunction are considered, thrombolysis improves early RV function and BNP compared with placebo.6

The rate of clot resolution over the first 24 h has been shown to change very little with heparin, whereas with thrombolysis, there is a 30%–35% reduction in perfusion defect.3 For patients with RV dysfunction, it is this early resolution of clot with thrombolysis which will prove to be beneficial in reducing early complications. One may also postulate that earlier resolution of DVT with thrombolysis may also improve outcomes, since further embolisation may be fatal. Of note, the study by Fasullo et al6 showed a trend towards better DVT resolution in patients receiving thrombolysis, only just missing statistical significance. It will take a large and well-constructed trial with mortality comparable with real-life data in the placebo arm to show mortality benefit with thrombolysis; until that time, surrogate data strongly suggest thrombolysis directly reduces the risk factors for death.

In addition to early PE-related mortality, there are important long-term outcomes from PE, in particular CTEPH. While it may not be common in all comers with PE, 2%–4% of cases,1 it is likely to be much more common in those patients who have had submassive PE. No study has been performed rigorously using right heart catheterisation to study the incidence of CTEPH postsubmassive PE, especially given the variation in definition. Nonetheless, despite its likely low incidence, in itself it carries a significant risk of death.1 Even if amenable to surgical endarterectomy, this is a very major surgical operation with its own mortality (<5%) and morbidity.8 The argument may be less persuasive than early mortality since the associations are less direct, but adds to the weight of the argument in favour of thrombolysis.

Many studies referenced in the AHA statement,3 in particular those by Kline et al9 and Fasullo et al,6 show lower long-term pulmonary arterial pressures and better RV function in those who were treated upfront with thrombolysis. How much of the improvement in RV function relates to more rapid relief of RV afterload cannot be certain, but the lower pulmonary pressures would suggest better clot resolution, which in itself is associated with lower 6-month mortality.10 Why anticoagulation fails to catch up with thrombolysis is not fully understood, but studies of plasmin-mediated cleavage of fibrin have demonstrated resistance to fibrinolysis in patients with CTEPH compared with those with acute PE.11 Allowing endogenous clot lysis to take place ‘passively’ using heparin alone may not be sufficient therefore to prevent progression to CTEPH in some patients. Identifying these patients upfront is not currently possible, but those with acute pulmonary hypertension are at the greatest risk of CTEPH.1 That many patients presenting with CTEPH have in the past received thrombolysis12 is not relevant, since many of these patients will have suffered previously unresolved PE.

While there can be little doubt that thrombolysis leads to faster and possibly more complete clot resolution, it is the risk of serious bleeding, in particular intracranial haemorrhage, which causes reticence when considering thrombolysis. This is a real concern and should not be taken lightly, but what we must consider is the balance of benefit against risk. A recent very large registry study of nearly 16 000 patients with PE showed a non-significant trend towards increased bleeding-related mortality at 90 days in those who received thrombolytics.13 While the mortality was nearly double in the thrombolysis group (1.16% vs 0.61%, p=0.16), in absolute terms the rate was very low. Given that the entire cardiac output transits through the lung, it has been argued that lower doses of thrombolytics could be used with equal efficacy. Two recent studies have done just this,14 ,15 showing equivalent clot resolution and lower rates of bleeding, although the numbers remain small in comparison with large registry studies.

It is the intention of the PEITHO investigators that this debate is settled once and for all,7 but for the reasons explained above, namely, lower overall than expected mortality and the use of rescue thrombolysis, the PE-related mortality signal may be watered down. Until the data provide a clear answer, we must use our judgement.

In summary, outcomes in patients with true submassive PE remain unacceptably high and thrombolysis has been shown to improve surrogate outcomes for mortality as well as long-term complications. The risks from thrombolysis are low, and when reduced doses are used, evidence so far suggests no decrease in benefit, but a further reduction in bleeding. The next patient you see with submassive PE will want you to act on your best judgement rather than hide behind a ‘lack of evidence’.


View Abstract


  • Disclaimer The views expressed in this article do not necessarily represent the personal views or practice of the author, but have been written to stimulate debate.

  • Competing interests Luke Howard has received research funding, speaker fees and fees for consultancy from Bayer.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles

  • Pulmonary vasculature
    David Jiménez José Luis Lobo Manuel Monreal Lisa Moores Mikel Oribe Manuel Barrón Remedios Otero Dolores Nauffal Ramón Rabuñal Reina Valle Carmen Navarro Consolación Rodríguez-Matute Celso Álvarez Francisco Conget Fernando Uresandi Drahomir A Aujesky Roger D Yusen on behalf of the PROTECT investigators Celso Álvarez Jose María Abaitúa Víctor Abraira Ángel Alonso Luis Javier Alonso Aitor Ballaz Marta Ballester Manuel Barrón Sem Briongos Eva Castañer Olalla Castro Francisco Conget José María Cuesta Teresa Elías Vicente Gómez Ignacio Gallego Mariano González Luis Gorospe Eva Guillaumet Concepción Iglesias David Jiménez Francisco López Mónica López María Lladó José Luis Lobo Pilar Lucio Jesús Marín María Martín Manuel Monreal Alfonso Muriel Dolores Nauffal Carmen Navarro Mikel Oribe Ana Osa Remedios Otero José Pamies María Victoria Piret Delfina Pozo Amador Prieto Ramón Rabuñal Consolación Rodríguez Nuria Rodríguez Carmen Rodrigo Miguel Ángel Santolaria Pilar Serrano Ana Testa Fernando Uresandi Reina Valle Sonia Velasco Agustina Vicente Jorge Vivancos Roger D. Yusen Javier Zamora Vanesa Zorrilla José Luis de Benito José Manuel del Rey
  • Pulmonary vasculature
    Nika Skoro-Sajer Gabriel Marta Christian Gerges Gerald Hlavin Patrick Nierlich Shahrokh Taghavi Roela Sadushi-Kolici Walter Klepetko Irene Marthe Lang
  • Editorial
    A John Simpson
  • Airwaves
    Andrew Bush Ian Pavord